PTC Therapeutics ( (PTCT) ) has issued an announcement.
On March 28, 2025, PTC Therapeutics announced that the European Commission adopted the negative opinion of the Committee for Medicinal Products for Human Use, deciding not to renew the conditional marketing authorization for Translarna (ataluren) in the European Economic Area. Despite this setback, the European Commission noted that individual EU member states could still allow the continued use of Translarna, highlighting its safety and benefits for patients with nonsense mutation Duchenne muscular dystrophy, a rare and severe genetic disorder.
More about PTC Therapeutics
PTC Therapeutics, Inc. is a global biopharmaceutical company dedicated to discovering, developing, and commercializing clinically differentiated medicines for rare disorders. The company focuses on providing access to best-in-class treatments for patients with unmet medical needs, leveraging its scientific expertise and global commercial infrastructure.
YTD Price Performance: 19.86%
Average Trading Volume: 747,519
Technical Sentiment Signal: Sell
Current Market Cap: $4.34B
See more data about PTCT stock on TipRanks’ Stock Analysis page.